A study of variations in the reported haemophilia A prevalence around the world

Haemophilia

Volumn 16, Issue 1, 2010, Pages 20-32

  Stonebraker, J S ^a   Bolton Maggs, P H B ^b   Michael Soucie, J ^c   Walker, I ^d   Brooker, M ^e  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e WORLD FEDERATION OF HEMOPHILIA   (Canada)

Author keywords

Economics; Epidemiology; Haemophilia A; Prevalence; World Federation of Hemophilia

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ARTICLE; CANADA; DISEASE SURVEILLANCE; DRUG MARKETING; ECONOMIC EVALUATION; GEOGRAPHIC DISTRIBUTION; HEALTH CARE FACILITY; HEALTH CARE FINANCING; HEALTH CARE PLANNING; HEALTH ECONOMICS; HEMOPHILIA A; HUMAN; MEDICAL INFORMATION; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; TREND STUDY; UNITED KINGDOM;

DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; HEMOPHILIA A; HUMANS; INCOME; PREVALENCE; WORLD HEALTH;

EID: 73949126440     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02127.x     Document Type: Article

References (87)

1. Aledort LM, Aster RH, Bidwell E. International Forum: Can a national all voluntary blood transfusion service by adequate blood component therapy cover actual and future needs of AHF? Vox Sang 1976, 31:296-320.
2. Report on the Annual Global Survey 2006 2007, Montreal, Canada, WFH
3. Bolton-Maggs PHB. Optimal haemophilia care versus the reality. Br J Haematol 2005, 132:671-82.
4. Chandy M. Management of haemophilia in developing countries with available resources. Haemophilia 1995, 1(Suppl 1):44-8.
5. Evatt BL. Demographics of hemophilia in developing countries. Semin Thromb Hemostasis 2005, 31:489-94.
6. Nathwani AC, Tuddenham EGD. Epidemiology of coagulation disorders. Baillière's Clin Haematol 1992, 5:383-439.
7. Srivastava A. Delivery of haemophilia care in the developing world. Haemophilia 1998, 4(Suppl 2):33-40.
8. Rosendaal FR, Briët E. The increasing prevalence of haemophilia. Thromb Haemostasis 1990, 63:145.
9. Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. Am J Hematol 1998, 59:288-94.
10. Srivastava A, Chuansumrit A, Chandy M, Duraiswamy G, Karagus C. Management of haemophilia in the developing world. Haemophilia 1998, 4:474-80.
11. Aledort LM. Unsolved problems in haemophilia. Haemophilia 1998, 4:341-5.
12. Evatt BL. The natural evolution of haemophilia care: developing and sustaining comprehensive care globally. Haemophilia 2006, 12(Suppl 3):13-21.
13. Skinner MW. Treatment for all: a vision for the future. Haemophilia 2006, 12(Suppl 3):169-73.
14. Ikkala E, Helske T, Myllylä G, Nevanlinna HR, Pitkänen P, Rasi V. Changes in the life expectancy of patients with severe haemophilia A in Finland in 1930-79. Br J Haematol 1982, 52:7-12.
15. Larsson SA. Life expectancy of Swedish haemophiliacs, 1831-1980. Br J Haemotol 1985, 59:593-602.
16. Antunes SV. Haemophilia in the developing world: the Brazilian experience. Haemophilia 2002, 8:199-204.
17. Evatt BL. Public health and international healthcare development for persons with haemophilia: Operation Improvement and Operation Access. Haemophilia 1998, 4(Suppl 2):54-8.
18. Evatt BL, Robillard L. Establishing haemophilia care in developing countries: using data to overcome the barrier of pessimism. Haemophilia 2000, 6:131-4.
19. Shapiro AD. A global view on prophylaxis: possibilities and consequences. Haemophilia 2003, 9(Suppl 1):10-18.
20. Srivastava A. Choice of factor concentrates for haemophilia: a developing world perspective. Haemophilia 2001, 7:117-22.
21. Stonebraker JS, Amand RE, Nagle AJ. A country-by-country comparison of FVIII concentrate consumption and economic capacity for the global haemophilia community. Haemophilia 2003, 9:245-50.
22. Tezanos Pinto M, Ortiz Z. Haemophilia in the developing world: successes, frustrations and opportunities. Haemophilia 2004, 10(Suppl 4):14-9.
23. Farrugia A. Safety and supply of hemophilia products: worldwide perspectives. Haemophilia 2004, 10:327-33.
24. Shapiro AD. Why is primary prophylaxis underutilized in the United States? Haemophilia 2003, 9:670-2.
25. Stonebraker JS, Amand RE, Bauman MV, Nagle AJ, Larson PJ. Modelling haemophilia epidemiology and treatment modalities to estimate unconstrained factor VIII demand. Haemophilia 2004, 10:18-26.
26. Evatt BL. Observations from Global Survey 2001: an emerging database for progress. Haemophilia 2002, 8:153-6.
27. World Development Indicators 2007 2007, http://www.worldbank.org, (), Washington, DC, World Bank
28. The OECD 2008, http://www.oecd.org, (), Paris, France, OECD
29. WFH Global Survey on Hemophilia 1999 edition 1999, Montreal, Canada, WFH
30. WFH Global Survey on Hemophilia 2000 edition 2000, Montreal, Canada, WFH
31. Report on the WFH Global Survey 2001 2001, Montreal, Canada, WFH
32. Report on the WFH Global Survey 2002 2002, Montreal, Canada, WFH
33. Report on the WFH Global Survey 2003 2004, Montreal, Canada, WFH
34. Report on the Annual Global Survey 2004 2005, Montreal, Canada, WFH
35. Report on the Annual Global Survey 2005 2006, Montreal, Canada, WFH
36. WHO/WFH Recommendations, June 1997. Haemophilia 1998, 4(Suppl 2):64-6.
37. Evatt B. Guide to Developing a National Patient Registry 2005, Montreal, QC, Canada, World Federation of Hemophilia
38. Jones P, Robillard L. The World Federation of Hemophilia: 40 years of improving haemophilia care worldwide. Haemophlilia 2003, 9:663-9.
39. World Population Prospects: The 2006 Revision and World Urbanization Prospects: The 2005 Revision 2006, http://esa.un.org/unpp, (), New York, NY, UN
40. Population Estimates for the U.S., Regions, Divisions, and States by 5-year Age Groups and Sex: Time Series Estimates, July 1, 1990 to July 1, 1999 and April 1 1990 Census Population Counts US Census Bureau 2000, http://www.census.gov/population/estimates/state/st-99-08.txt, (), Washington DC
41. Canadian Hemophilia Registry Factor VIII (Hemophilia A), all Ages, April 17, 2008 2008, http://www.fhs.mcmaster.ca/chr, (), Toronto, Canada, AHCDC
42. Canadian Hemophilia Registry Factor VIII (Hemophilia A), pediatric/adult, April 27, 2007 2007, http://www.fhs.mcmaster.ca/chr, (), Toronto, Canada, AHCDC
43. Canadian Hemophilia Registry Factor VIII Deficiency, pediatric/adult, May 9, 2006 2006, http://www.fhs.mcmaster.ca/chr, (), Toronto, Canada, AHCDC
44. Canadian Hemophilia Registry Factor VIII (Hemophilia A), pediatric/adult, May 8, 2005 2005, http://www.fhs.mcmaster.ca/chr, (), Toronto, Canada, AHCDC
45. Canadian Hemophilia Registry Factor VIII Deficiency, pediatric/adult, July 7, 2004 2004, http://www.fhs.mcmaster.ca/chr, (), Toronto, Canada, AHCDC
46. Canadian Hemophilia Registry Factor VIII (Hemophilia A), Pediatric/Adult, May 29, 2003 2003, http://www.fhs.mcmaster.ca/chr, (), Toronto, Canada, AHCDC
47. Blanchette P, Rivard G, Israels S. A survey of factor prophylaxis in the Canadian haemophilia A population. Haemophilia 2004, 10:679-83.
48. Walker IR, Julian JA. Causes of death in Canadians with haemophilia 1980-1995. Haemophilia 1998, 4:714-20.
49. Walker I, Pai M, Akabutu B. The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates. Transfusion 1995, 35:548-51.
50. Walker I. Survey of the Canadian hemophilia population. Can J Public Health 1991, 82:127-9.
51. Rasi V, Ikkala E. Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 1990, 76:369-71.
52. Rasi V, Ikkala E, Myllylä G, Nevanlinna HR. Low prevalence of antibodies against human immunodeficiency virus in Finnish haemophiliacs. Vox Sang 1991, 60:159-61.
53. Bauduer F, Degioanni A, Ducout L, Scribans C, Dutour O. Distribution of haemophilia in the French Basque country. Haemophilia 2002, 8:735-9.
54. Koumbarelis E, Rosendaal FR, Gialeraki A. Epidemiology of haemophilia in Greece: An overview. Thromb Haemostasis 1994, 72:808-13.
55. Mandalaki T. Management of Haemophilia in Greece. Thromb Haemostasis 1976, 35:522-30.
56. Iorio A, Oliovecchio E, Morfini M, Mannucci PM. Italian Registry of haemophilia and allied disorders. Objectives, methodology and data analysis. Haemophilia 2008, 14:444-53.
57. Ghirardini A, Schinaia N, Chiarotti F. Epidemiology of hemophilia and of HIV infection in Italy. J Clin Epidemiol 1994, 47:1297-306.
58. Fututake K. Current status of hemophilia patients and recombinant coagulation factor concentrates in Japan. Sem Thromb Hemostasis 2000, 26:29-32.
59. Plug I, van der Bom JG, Peters M. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood 2004, 104:3494-500.
60. Plug I, van der Bom JG, Peters M. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemostasis 2006, 4:510-6.
61. Triemstra M, Rosendaal FR, Smit C, Van der Ploeg HM, Briët E. Mortality in patients with hemophilia: changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Internal Med 1995, 123:823-7.
62. Smit C, Rosendaal FR, Varakamp I. Physical condition, longevity, and social performance of Dutch haemophiliacs, 1972-85. Br Med J 1989, 298:235-8.
63. Rosendaal FR, Varekamp I, Smit C. Mortality and causes of death in Dutch haemophiliacs 1973-86. Br J Haematol 1989, 71:71-6.
64. Martin-Villar J, Ortega F, Magallon M. Management of hemophilia in Spain. Thromb Haemostasis 1976, 35:537-43.
65. Larsson SA, Nilsson IM, Blombäck M. Current status of Swedish hemophiliacs. Acta Med Scand 1982, 212:195-200.
66. Nilsson IM. Management of haemophilia in Sweden. Thromb Haemostasis 1976, 35:510-21.
67. UKHCDO Annual Report 2008 & Bleeding Disorder Statistics for 2007 2008, Manchester UK, UKHCDO
68. Annual Report 2007 Annual Returns 2006 2007, Manchester UK, UKHCDO
69. Annual Report 2006 Annual Returns 2004 and 2005 2006, Manchester UK, UKHCDO
70. Annual Report 2005 and Annual Returns for 2003 2005, Manchester UK, UKHCDO
71. Annual Report 2004 and Annual Returns for 2002 2004, Manchester UK, UKHCDO
72. National Haemophilia Database: Report on the Annual Returns for 2000 and 2001 2003, Manchester UK, UKHCDO
73. Report on the annual returns for 1999 2002, Oxford UK, UKHCDO
74. Report on the annual returns for 1998 2000, Oxford UK, UKHCDO
75. Report on the annual returns for 1997 1999, Oxford UK, UKHCDO
76. Rizza CR, Spooner RJD, Giangrande PLF. Treatment of haemophilia in the United Kingdom 1981-1996. Haemophilia 2001, 7:349-59.
77. Rizza CR, Spooner RJD. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of haemophilia centres in the United Kingdom. Br Med J 1983, 28:929-33.
78. Biggs R. Haemophilia treatment in the United Kingdom from 1969 to 1974. Br J Haematol 1977, 35:487-504.
79. Linden JV, Kolakoski MH, Lima JE, Du P, Lipton RA. Factor concentrate usage in persons with hemophilia in New York State. Transfusion 2003, 43:470-5.
80. Eyster ME, Lewis JH, Shapiro SS. The Pennsylvania hemophilia program 1973-1978. Am J Hematol 1980, 9:277-86.
81. Summary report NHLI's blood resources studies, June 30, 1972 1972, Washington, DC, U.S. Government Printing Office
82. Skinner MW. WFH - the cornerstone of global development: 45 years of progress. Haemophilia 2008, 14(Suppl 3):1-9.
83. Arnold DM, Julian JA, Walker IR. Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up. Blood 2006, 108:460-4.
84. Darby SC, Kan SW, Spooner RJ. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007, 110:815-25.
85. Helgason A, Nicholson G, Stefansson K, Donnelly P. A reassessment of genetic diversity in icelanders: strong evidence from multiple loci for relative homogeneity caused by genetic drift. Ann Hum Genetics 2003, 67:281-97.
86. Ludlam CA, Lee RJ, Prescott RJ. Haemophilia care in central Scotland 1980-94. I. Demographic characteristics, hospital admissions and causes of death. Haemophilia 2000, 6:494-503.
87. Srivastava A, Hoots WK, Soucie JM, Ludlam CA. Linking the world with training and research for improving haemophilia care. Haemophilia 2008, 14(Suppl 3):43-8.